

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : C12N 15/00, 15/09, 15/11, 15/12, 15/13, C07K 4/00, 14/00, 14/435, 14/47, 14/725, C07H 21/00, 21/04		A1	(11) International Publication Number: WO 95/28481 (43) International Publication Date: 26 October 1995 (26.10.95)
(21) International Application Number: PCT/US95/04803 (22) International Filing Date: 14 April 1995 (14.04.95)		(81) Designated States: CA, JP, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).	
(30) Priority Data: 229,285 18 April 1994 (18.04.94) US		Published <i>With international search report.</i>	
(71) Applicant: NEW YORK SOCIETY FOR THE RUPTURED AND CRIPPLED MAINTAINING THE HOSPITAL FOR SPECIAL SURGERY [US/US]; 535 East 70th Street, New York, NY 10021 (US).			
(72) Inventors: FRIEDMAN, Steven, M.; 24 Windsor Road, Tenafly, NJ 07670 (US). CROW, Mary, K.; 17 East 89th Street, New York, NY 10128 (US). LI, Yixin; Apartment 4M, 30 East End Avenue, New York, NY 10028 (US). TUMANG, Joseph, R.; 85-41 75th Street, Woodhaven, NY 11421 (US). SUN, Guang-Rong; 333 East 93rd Street, New York, NY 10028 (US).			
(74) Agents: LUDWIG, S., Peter et al.; Darby & Darby P.C., 805 Third Avenue, New York, NY 10022 (US).			

(54) Title: CONSERVED T-CELL RECEPTOR SEQUENCES

(57) Abstract

Four unique transcripts have been isolated from the β chain of the T-cell receptor in T-cells in the synovial tissue of a patient with rheumatoid arthritis. Two of these transcripts were isolated from fresh synovial tissue and two were isolated from a T-cell line derived from the synovial tissue. The sequences of the four transcripts are highly homologous, with a conserved amino acid sequence of IGQ_N in the highly diverse V-D junction. The α chain and the antigenic specificity of the T-cell line derived transcripts has also been characterized.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Larvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

CONSERVED T-CELL RECEPTOR SEQUENCES

This application is a continuation-in-part of Serial No. 07/766,751 filed September 27, 1991. This work was 5 supported by grants from the National Institutes of Health.

BACKGROUND OF THE INVENTION

T lymphocytes recognizes antigens through the T cell antigen receptor (TCR) complex. The TCR is a clone-specific 10 heterodimer on T cells, which recognizes its target antigen in association with a major histocompatibility antigen. Moreover, the TCR is highly polymorphic in different T cells. Approximately 90 percent of peripheral blood T cells express a TCR consisting of an α polypeptide and a β polypeptide and 15 a small percentage of T cells express a TCR consisting of a γ polypeptide and a δ polypeptide. See Davis and Bjorkman, 1988, *Nature* 334:395-402; Marrack and Kappler, 1986, *Sci. Amer.* 254:36; Meuer et al., 1984, *Ann. Rev. Immunol.* 2:23-50; Brenner et al., 1986, *Nature* 322:145-159; Krangel et al., 1987, *Science* 237:1051-1055; Hata et al., 1987, *Science* 238:678-682; 20 Hochstenbach et al., 1988, *J. Exp. Med.* 168:761-776).

The chains of the T cell antigen receptor of a T cell clone are each composed of a unique combination of domains designated variable (V), diversity (D), joining (J), and 25 constant (C) (Siu et al., 1984, *Cell* 37:393; Yanagi et al., 1985 *Proc. Natl. Acad. Sci. USA* 82:3430). Hypervariable regions also have been identified (Patten et al., 1984, *Nature* 312:40; Becker et al., 1985, *Nature* 317:430). In each T cell 30 clone, the combination of V, D and J domains of both the alpha and the beta chains or both the delta and gamma chains and defines a unique antigen binding site in each T-cell clone.

In contrast, the C domain does not participate in antigen binding.

TCR genes, like immunoglobulin genes, consist of regions which arrange during T cell ontogeny (Chien et al., 5 1984, *Nature* 312:31-35; Hedrick et al., 1984, *Nature* 308:149-153; Yanagi et al., 1984, *Nature* 308:145-149). In genomic DNA, each TCR gene has V, J, and C regions; TCR β and δ polypeptides also have D regions. The V, D, J and C regions are separated from one another by spacer regions in the DNA. There are 10 usually many variable region segments and somewhat fewer diversity, junctional, and constant regions segments. As a lymphocyte matures, these various segments are spliced together to create a continuous gene sequence consisting of one V, (D), J, and C regions. TCR diversity, and thus T cell specificity, 15 derives from several sources, (Barth et al., 1985, *Nature* 316:517-523; Fink et al., 1986, *Nature* 321:219-225) including: a multiplicity of germline gene segments (Chien et al., 1984, *Nature* 309:322-326; Malissen et al., 1984, *Cell* 37:1101-1110; Gascoigne et al., 1984, *Nature* 310:387-391; Kavaler et al., 20 1984, *Nature* 310:421-423; Siu et al., 1984, *Nature* 311:344-349; Patten et al., 1984, *Nature* 312:40-46), combinatorial diversity through the assembly of different V, D, J, and C segments (Siu et al., 1984, *Cell* 37:393-401; Goverman et al., 1985, *Cell* 40:859-867), and junctional flexibility, N-region diversity and 25 the use of either multiple D regions or any of the three translational reading frames for $D\beta$ segments. As a result of these mechanisms, TCRs are generated which differ at their N-terminal (called variable, or V regions, constructed from combinations of V, D, and J gene segments) but are the same 30 elsewhere, including their C-terminal (called constant regions). Therefore, an infinite number of TCRs can be established.

The $V\beta$ gene of the TCR appears to resemble most closely the immunoglobulin V gene in that it has three gene 35 segments, $V\beta$, $D\beta$, and $J\beta$, which rearrange to form a contiguous $V\beta$ gene (Siu et al., 1984, *Cell* 37:393-401). The β locus has been well characterized in mice, where it spans 700-800 kilobases of DNA and is comprised of two nearly identical C

regions tandemly arranged with one D element and a cluster of 5-6 J elements 5' to each (Kronenberg et al., 1986, *Ann Rev. Immunol.* 3:537-560). Approximately twenty to thirty V β regions are located upstream (5') to the D, J, and C elements (Behlke et al., 1985, *Science*, 229:566-570) although V β genes may also be located 3' to the murine C β genes (Malissen et al., 1986, *Nature* 319:28). Study of the structure and diversity of the human TCR β -chain variable region genes has led to the grouping of genes into distinct V β subfamilies (Tillinghast et al., 1986, *Science* 233:879-883; Concannon et al., 1986, *Proc. Natl. Acad. Sci. USA* 83:6598-6602; Borsig et al., 1987, *J. Immunol.* 139:1952-1959).

The γ TCR gene was identified, first in mice (Saito et al., 1984, *Nature* 309:757-762; Kranz et al., 1985, *Nature* 313:762-755; Hayday et al., 1985, *Cell* 40:259-269) and then in humans (Lefranc et al., 1985, *Nature* 316:464-466; Murre et al., 1985, *Nature* 316:549-552). The human γ TCR locus appears to consist of between five and ten variable, five joining, and two constant region genes (Dialynas et al., 1986, *Proc. Natl. Acad. Sci. USA* 83:2619).

The TCR α and δ locus are adjacent to one another on human chromosome 14. Many TCR δ coding segments are located entirely within the α gene locus (Satyanarayana et al., 1988, *Proc. Natl. Acad. Sci. USA* 85:8166-8170 Chien et al., 1987, *Nature* 330:722-727; Elliot et al., 1988, *Nature* 331:627-631). It is estimated that there are a minimum of 45-50 V α regions (Becker et al., *Nature* 317:430-434) whereas there are only approximately 10 V δ regions (Chien et al., 1987, *supra*). Nucleic acid sequences of TCR α genes have been reported (Sim et al., 1984, *Nature* 312:771-775; Yanagi et al., 1985, *Proc. Natl. Acad. Sci. USA* 82:3430-3434; Berkout et al., 1988, *Nucl. Acids Res.* 16:5208).

Rheumatoid arthritis (RA) is a chronic, recurrent, inflammatory disease primarily involving joints, affecting 1-3% of North Americans. Three times the number of women are afflicted with RA than men. Severe RA patients tend to exhibit extra-articular manifestations including vasculitis, muscle atrophy, subcutaneous nodules, lymphadenopathy, splenomegaly

and leukopenia. Spontaneous remission may occur; other patients have brief episodes of acute arthritis with longer periods of low-grade activity; still others progress to severe deformity of joints. It is estimated that about 15% of RA 5 patients become completely incapacitated ("Primer on the Rheumatic Diseases," 8th edition, 1983, Rodman, G.P. & Schumacher, H.R. Eds., Zvaifler, N.J., Assoc. Ed., Arthritis Foundations, Atlanta, Ga.).

The antigenic stimulus initiating the immune response 10 and consequent inflammation is unknown. Certain HLA types (DR4, Dw4, Dw14 and DR1) have an increased prevalence of RA, perhaps leading to a genetic susceptibility to an unidentified factor which initiates the disease process. Relationships between Epstein Barr virus and RA have been suggested.

Many cell types, notably macrophages, synoviocytes 15 and polymorphonuclear leukocytes, participate in the complex inflammatory response which effects joint destruction in R.A. However, a central role for T lymphocytes is suggested by: 1) the rich infiltration of activated T cells at the primary site 20 of RA disease, the synovial tissue (van Boxel, J.A., et al., 1975; N. Engl. J. Med., 293:517; Panayi, J.S. et al., 1992, Arthritis Rheum. 35:729); 2) genetic studies linking RA disease 25 susceptibility to a defined amino acid sequence in the third hypervariable region of the DR β chain of the major histocompatibility complex (MHC) class II molecule (P. Gregersen, J. Silver, R. J. Winchester, 1987, Arthritis Rheum. 30:1205); 3) animal models of chronic arthritis in which antigen-specific T cells are capable of transferring disease 30 to naive recipients (R. Holmdahl, L. Klareskog, K. Rubin, E. Larsson, H. Wigzell, 1985, Scand. J. Immunol. 22:295; W. van Eden et al., 1985, Proc. Natl. Acad. Sci. USA, 1985, 82:5117); and 4) amelioration of arthritis, both in murine models of 35 autoimmune disease and in patients with RA, by administration of monoclonal antibody (mAb) reactive with the CD4 $^+$ T cell subset (G. E. Rangers, S. Sriram, S. M. Cooper, 1985, J. Exp. Med. 162:11104; G. Horneff, G. R. Burmester, F. Emmrich, J. R. Kalden, 1991, Arthritis Rheum. 34:129).

Previous studies designed to correlate TCR structure with antigen-MHC molecular complex recognition have emphasized the importance of critical amino acid residues in each of the three polymorphic CDR regions of both α and β chains, with CDR3 playing a dominant role. In both the murine and human systems, T cells specific for a particular peptide--MHC complex often utilize a characteristic amino acid or sequence cluster in the CDR3 region (S.M. Hedrick et al., 1988, *Science* 239:1541). Recent studies demonstrate that the introduction of charge altering amino acids in a well defined antigenic peptide results in a T cell response characterized by antigen-specific TCRs which have incorporated reciprocal charge changes in the CDR3 amino acid residues of both α and β chains (J.L. Jorgensen et al., 1992, *Nature* 355:224). This result suggests that these TCR residues bind directly to the antigenic peptide. In a related study, it was found that the murine TCR repertoire recognizing foreign peptides which are highly homologous to self is markedly constrained with respect to TCR V α and V β gene usage, CDR3 length, and the presence of canonical amino acid residues in the CDR3 domain (J.-L. Casanova et al., 1991, *J. Exp. Med.* 174:1371). These data suggest that pathogenic T cells mediating autoimmune disease will express TCR which share crucial structural characteristics.

Further support for this hypothesis is found in studies of other autoimmune diseases. Myelin basic protein (MBP) specific Th cells induce experimental allergic encephalomyelitis (EAE) (S.S. Zamvil et al., 1988, *J. Exp. Med.* 167:1586; J.L. Urban et al., 1988, *Cell* 54:577; F.R. Burns et al., 1989, *J. Exp. Med.* 169:27). Encephalitogenic T cell clones are strongly biased with respect to V β and V α gene usage as well as CDR3 region structure (D.P. Gold et al., 1992, *J. Immunol.* 148:1712). Recently, it has been shown that TCR V β transcripts isolated from central nervous system lesions of patients with multiple sclerosis (MS) exhibit sequence motifs in the CDR3 region homologous with those expressed by encephalitogenic MBP reactive murine T cell clones (R. Martin et al., 1991, *J. Exp. Med.* 173:19; J.R. Oksenberg et al., 1993, *Nature* 362:68).

While the importance of T cells in RA appears clear, neither the antigen specificity nor the structure of the TCR expressed by disease-inducing T cells has been determined. In an attempt to identify pathogenic T cells among the vast number present in the inflamed joint, investigators have applied molecular techniques to detect T cells which: 1) share TCR structural features, i.e. restricted usage of particular TCR variable gene elements, or 2) are "oligoclonal" with respect to the highly polymorphic antigen binding CDR3 region of the TCR, suggesting antigen-driven expansion at the site of pathology. To date, this approach has yielded conflicting results. Several laboratories have reported evidence of oligoclonality and over-usage of particular TCR V gene products among RA joint-derived T cells (M.D. Howell et al., 1991, *Proc. Natl. Acad. Sci. USA* 88:10921; X. Paliard et al., 1991, *Science* 253:325; W. V. Williams et al., 1992, *J. Clin. Invest.* 90:326). However, the TCR V gene families implicated vary from study to study and still other investigations find no evidence for TCR skewing in RA (Y. Uematsu et al., 1991, *Proc. Natl. Acad. Sci. USA* 88:8534; J. M. van Laar et al., 1991, *Clin. Exp. Immunol.* 83:353).

SUMMARY OF INVENTION

Four unique V β 17 transcripts encoding conserved CDR3 regions of the T cell receptor of RA patients has now been discovered. These unique transcripts while not identical, are highly homologous in an otherwise variable region of the TCR. Also, within these transcripts is a highly conserved sequence IGO_N (sequence I.D. No.13). These transcripts were isolated from the synovial tissue of a RA patient and a cell line expanded from synovial tissue T-cells.

It has also been discovered that two unique α chains with conserved CDR3 sequences are utilized by the unique T cell clones.

Methods for diagnosing and treating RA with the peptides encoded by the transcripts and/or monoclonal antibodies specific for the peptides is also part of this invention.

DESCRIPTION OF THE FIGURES

Figure 1 depicts mononuclear cells (MNC) from healthy subjects, patients with seropositive RA, patients with non-RA inflammatory arthritis, and patients with systemic lupus erythematosus (SLE) that were analyzed by indirect immunofluorescence for expression of V β 17 TCR gene products. Results for peripheral blood (PB) are shown in the top panel and for synovial fluid (SF) in the bottom panel and are expressed as % of cells reactive with the anti-TCR V β mAb/% of cells reactive with anti-CD3 mAb.

Figure 2 depicts MNC isolated from synovial fluid and analyzed by indirect immunofluorescence for expression of the T cell surface epitopes indicated. Fluorescence is demonstrated on the abscissa (log scale) and cell number on the ordinate (linear scale) of each cytofluorograph histogram.

Figure 3 depicts two color immunofluorescence analysis of SF T cells. SF T cells were stained with anti-V β (left panel) or anti-V β 17 (right panel) mAb.

Figure 4 depicts the CDR3 sequences of dominant V β 17 transcripts identified among freshly isolated synovial tissue T cells (V β 17seq1 and seq2) and culture 5 derived T cell clones expanded *in vitro* (V β 17seq3 and seq4). The conserved amino acid residues at the N-D-N area are presented in boldface.

Figure 5 depicts the nucleotide and deduced amino acid sequences in the CDR3 regions for V α 2.3 (A) and V α 3.1 (B). The V α 2.3, containing a J α (IGRJa09) segment, accompanies V β 17seq3 and the V α 3.1, using a J α k segment, is linked to V β 17seq4 expressing in culture 5-derived T cell clones.

Figure 6 shows the proliferation of synovial tissue T cell clones induced by EBV-transformed B cell lines.

DETAILED DESCRIPTION OF THE INVENTION

The invention is directed to unique α/β T cell receptor (TCR) sequences which are conserved in the synovial tissue of persons afflicted with RA. These four sequences show sequence homology in the complementarity-determining-region (CDR3), which is normally a highly variable region of the TCR.

Both the α and β chains of these transcripts have been characterized, as well as their antigenic specificity.

The first step in isolating these transcripts was to identify the type of T cell which is pathogenic in RA and characterize the relevant antigens that maintain their chronic activation. This was done by utilizing a panel of murine mAb reactive with the products of particular TCR V β gene families. The results demonstrated the selective increase in the percentage of T cells bearing the V β 17 TCR sequence in the peripheral blood (PB) and synovial fluid (SF) from patients with RA.

In order to evaluate the pathogenic potential of the oligoclonal V β 17 synovial T cells, isolation of these cells *in vitro* and characterization of the TCR α /B chain structure and antigenicity had to be done. To accomplish this, one patient with "classic" RA was followed for eighteen months and then T cells were explanted from his synovium. The unique transcripts were isolated from both the fresh synovium T cells and a cell line generated from the synovial tissue T cells.

Two of these transcripts, designated V β 17seq1 (amino acid sequence - seq. I.D. No. 1; nucleotide sequence - seq. I.D. No. 2) and V β 17seq2 (amino acid sequence - seq. I.D. No. 3; nucleotide sequence - seq. I.D. No. 4), were isolated from V β 17 cDNA clones derived from fresh synovial tissue. The other two of these sequences, designated V β 17seq3 (amino acid sequence - seq. I.D. No. 5; nucleotide sequence - seq. I.D. No. 6) and V β 17seq4 (amino acid sequence - seq. I.D. No. 7; nucleotide sequence - seq. I.D. No. 8) were isolated from a cell line generated *in vitro* from synovial tissue T cells.

These four transcripts, while not identical, contain highly homologous sequences. The nucleotide and deduced amino acid sequences in the CDR3 region are shown in Figure 4.

Comparison of the sequences show that amino acid residue "I" at position 95 and "N" at position 99 is found in all four transcripts. It should be noted that residue N at position #99 is encoded by the germline J β 2.1 segment in V β 17seq2, 3 and 4 but the same residue in V β 17seq1 is not germline encoded but results from the process of N region

nucleotide addition which generates diversity in the antigen binding VDT region. See Lieber, M.R. et. al., *Proc. Nat'l. Acad. Sci. USA*, 1988, 85:8588.

Furthermore, homology of the sequences of transcripts 5 $V\beta 17$ seq1 and $V\beta 17$ seq3, in the CDR3, region is 78.5% at the nucleotide level and 86.4% at the amino acid level. Also, 4 out of 5 amino acids, IGQ_N (seq. I.D. No. 13), at residues #95-99, in the highly diverse V-D junction, are conserved in both transcripts.

10 Without being bound by any theory, it is believed that the four dominant transcripts recognize the same joint-localized antigen and that the conserved amino acids, "I" at position #95 and "N" at position #99 in the CDR3 region of the $TCR\beta$ chain may prove crucial for antigen recognition.

15 Because antigen recognition is a function of both $TCR\alpha$ and β , the α chain usage of the cell line derived T-cell clones characterized also (Fig. 5). $V\beta 17$ seq3 expresses the $V\alpha 2.3$, and had an α rearrangement of $V\alpha 2.3-J\gamma$ (IGRJa09)- $C\alpha$ (amino acid sequence - seq. I.D. No. 9 and nucleotide sequence 20 - seq. I.D. No. 10). The expression of $V\alpha 2.3$ is of interest because recent reports have shown a selective increase in $V\alpha 2.3$ T cells in the synovial fluid of RA patients. See Pluschke, G. et al., *Eur. J. Immunol.*, 1991, 21:749; Bröker, B.M. et al., *Arthritis Rheum.*, 1993, 9:1234. $V\beta 17$ seq4 expressed $V\alpha 3.1-J\alpha K-C\alpha$ (amino acid sequence - seq. I.D. No. 11; nucleotide 25 sequence - seq. I.D. No. 12) (Fig. 5).

Lastly, the antigen specificity of the culture derived T cell clones was determined. The synovial T cells expressing the conserved CDR3 sequences respond to the alleles 30 of the RA associated DR4 molecule.

These T cell clones which utilize the same $V\beta$ gene, are highly homologous in the antigen binding CDR3 region, and are reactive with or restricted by the HLA DR4 antigen probably have pathogenic potential in the rheumatoid process. This is 35 supported by: 1) mAb staining results in which only RA, but not other arthropathies, is characterized by an expansion of $V\beta 17^+$ T cells; 2) data from other laboratories demonstrating the selective representation of $V\beta 17$, 14 and 3 among RA synovial

T cells (Howell, M.D. et al., *Proc. Nat'l. Acad. Sci. USA*, 1991, 88:10921; Paliard et al., *Science*, 1991, 253:325; Williams, W.V., et al., *J. Clin. Invest.*, 1992, 90:326); and most compelling, 3) a CDR3 sequence highly homologous to that 5 in our V β 17seq2 ("IQG_N") has been identified among the expanded, oligoclonal V β 14 TCR transcripts isolated from synovial fluid and tissue T cells of a DR4 $^+$, RF $^+$ patient suffering from juvenile rheumatoid arthritis. See Grom et al., *Proc. Nat'l. Acad. Sci. USA*, 1993, 90:11104.

10 The isolation and in vitro growth of clones expressing TCR sequences homologous to the dominant V β 17 sequences identified in fresh synovium have allowed elucidation of the complete structure of the α β TCR expressed by potentially pathogenic RA T cells. These clones can also be 15 used to assess reactivity against a panel of potentially important self antigens, including joint-restricted antigens postulated to be targets of autoimmune attack, e.g. type II collagen, proteoglycans, heat shock proteins, as well as an array of synthetic peptides containing the sequence shared by 20 RA-associated DR molecules, QKRAA (seq. I.D No. 14).

These sequences could also be used as a confirmatory diagnostic tool for RA. A diagnosis of RA may be made based upon clinical features and a in vitro assay using probes homologous to the conserved TCR sequences could confirm that 25 the patient is indeed suffering from RA, as opposed to other diseases affecting the joints. Such a method would entail contacting the bodily fluid of a person suspected of suffering from RA with a probe homologous to the conserved TCR sequences. Bodily fluid would include, but not be limited to, synovial 30 fluid. The presence or absence of the conserved TCR sequence determined by any method known to those skilled in the art. Specific embodiments would include probes homologous to any one of the CDR3 sequences of V β seq1, V β 17seq2, V β 17seq3 and V β 17seq4 or other portions thereof. Another preferred 35 embodiment would include probes homologous to the conserved CDR3 α -chain sequences. Yet another preferred embodiment would be a probe homologous to the nucleotide sequence encoding the amino acid sequence IQG_N.

The unique TCR sequences could also be used for immunotherapy for RA, for example by using them as "blocking" antigenic peptides, activation of immunoregulatory cells, induction of an anti-TCR antibody or in mAb mediated deletion 5 of the pathogenic V gene expressing T cells. Fragments consisting of amino acids homologous to the unique TCR sequence could be administered to a patient directly. Such sequences would act by blocking the TCR of the T cells making the T cells unable to attack the antigens of the patient. The specific 10 peptides to be used in such a method would be homologous to the amino acid sequence of V β 17seq1, V β 17seq2, V β 17seq3 or V β 17seq4. More specifically, a peptide homologous to the sequence IGQ_N could also be used.

In an alternative method of immunotherapy, mAb could 15 be produced, by conventional methods known in the art, which is directed to the unique TCR sequences. These mAb directed to the unique TCR sequences would target the unique TCR sequences which are believed to be pathogenic.

Specific monoclonal antibodies to be used in such a 20 method would include mAb which recognize the CDR3 sequences of V β seq1, V β seq2, V β seq3 or V β 17seq4 or portions thereof. A mAb directed to IGQ_N would also be useful.

Either the peptides or the mAb could be administered to an RA patient, for example in his synovial fluid, 25 systemically, or orally, in a suitable pharmaceutical carrier.

Example 1

In order to directly evaluate TCR V gene usage in the RA T cell repertoire, a panel of monoclonal antibodies specific 30 for human TCR V β gene products was utilized. Control subjects included 25 healthy volunteers (female/male = 2.4, mean age = 43.3). Disease controls included patients with systemic lupus erythematosus (female/male = 10.0 ; mean age = 40) or 19 patients with non-RA inflammatory arthritis, including 35 osteoarthritis, gout, Reiter's syndrome and monoarticular arthritis; (female/male = 2.0; mean age = 59.5). RA patients were defined using American Rheumatism Association criteria (Arnett et al., 1988, *Arthritis Rheum.*, 31:315-324). Patients

were not selected with respect to medical therapy, which included aspirin, nonsteroidal antiinflammatory drugs, corticosteroids, methotrexate, gold, hydroxychloroquine, or sulfasalazine. Serum samples from RA patients were assayed by 5 latex fixation to determine if the patients were seropositive for RF. PB mononuclear cells (MNC) from some subjects were characterized for HLA DR haplotype using standard serologic reagents.

Peripheral blood samples were obtained by 10 venipuncture, and SF samples were obtained at the time of therapeutic arthrocentesis. ST specimens were obtained from the Department of Pathology at The Hospital for Special Surgery following therapeutic arthroscopic synovectomy, open synovectomy, or total joint replacement. Synovial tissue was minced 15 under sterile conditions and incubated in 20 ml. of an enzyme preparation containing RPMI 1640 (GIBCO Laboratories, Grand Island, NY), 20% fetal calf serum (Whittaker Bioproducts, Inc., Walkersville, MD), 1% penicillin and streptomycin, 1% glutamine (GIBCO), 0.5 mg/ml collagenase, 0.15 mg/ml DNase, and 0.1 mg/ml 20 hyaluronidase (Sigma Chemical Co., St. Louis, MO) at 37°C., 5% CO₂ for 2-4 hours. Tissue was then mechanically disrupted using forceps and scalpel and pressed through a mesh sieve.

MNC were isolated from PB, SF, or ST digest on a Ficoll-Hypaque (Pharmacia, Uppsala, Sweden) gradient. In some 25 cases, T cells were selectively enriched by rosetting of MNC with sheep red blood cells (SRBC) followed by incubation at 4°C for 16 hours and subsequent fractionation of rosetted and unrosetted cells over Ficoll-Hypaque.

The T cells were stained with the following 30 monoclonal antibodies: OKT3 (anti-CD3, pan-T); OKT4 (anti-CD4, helper/inducer subset); OKT8 (anti-CD8, suppressor/cytotoxic subset, American Type Culture Collection, Rockville, MD); β V3 (reactive with TCR V β 3, T Cell Diagnostics, Cambridge, MA); C37 (reactive with TCR V β 5.2/5.3, Wang et al., *Hybridoma*, 1986, 35 5:179); OT145 (reactive with TCR V β 6.7a, Li et al., *J. Exp. Med.*, 1990, 171:221); 16G8 (reactive with TCR V β 8, T Cell Diagnostics); S511 (reactive with TCR V β 12, Bigler et al., *J. Exp. Med.*, 1983, 158:1000; C1 (reactive with TCR V β 17, Freedman

et al., *J. Exp. Med.*, 1991, 174:891) and F1 (reactive with TCR V α 2.3, Janson et al., *Cancer Immunol. Immunother.*, 1989, 28:225).

1-2 \times 10⁵ MNC or T cells were incubated with buffer
5 alone or a saturating concentration of mAb at 4°C for 30 minutes. Cells were then washed three times and incubated with a saturating concentration of fluorescein-labeled F(ab'),
fragments of goat anti-mouse IgG (Tago, Inc., Burlingame, CA)
at 4°C for 30 minutes. After 3 washes in buffer, the cells
10 were analyzed on a cytofluorograph. In some cases, two color immunofluorescence analysis was performed. The above procedure was followed by a blocking step, with cells incubated at 4°C for 30 minutes with an irrelevant murine mAb (anti-trinitrophenol). After three washes, the cells were incubated
15 with a phycoerythrin-labeled murine mAb, washed, and prepared for analysis on a cytofluorograph. Cell fluorescence was analyzed on an Ortho IIs cytofluorograph, gating on the small, nongranular lymphocyte population. The percentage of cells fluorescent with buffer or irrelevant control murine mAb and
20 fluorescein-labeled goat anti-mouse IgG alone was subtracted. Cytofluorograph histograms of cells stained with anti-TCR mAb exhibited a peak of fluorescence distinct from the negative peak and with fluorescence intensity approximating that of cells stained with anti-CD3 mAb.

25

Example 2

PB MNC from healthy subjects and from patients with seropositive RA, non-RA inflammatory arthritis, or SLE were isolated and the percentage of CD3-positive cells expressing
30 the TCR V β gene product identified by a panel of anti-TCR mAb determined by indirect immunofluorescence analysis. The mean percentage of T cells reactive with mAb C37 (V β 5.2, 5.3), OT145 (V β 6.7a), 16G8 (V β 8), or S511 (V β 12) is similar in each of the groups tested (Table 1), a result consistent with
35 previous studies of T cell repertoire in autoimmune disease which used these monoclonal reagents (Posnett et al, *J. Immunol.*, 1988, 141:1963; Gudmundsson et al., *Scand. J. Immunol.*, 1992, 36:681). In contrast, analysis of CD3-positive

PB cells reactive with the more recently available mAb Cl, specific for the V β 17 TCR gene product, demonstrates a significant increase in the mean percentage of V β 17-positive cells in RA patients when compared with the normal subjects or control patients ($p = 0.002$) (Table 1 and Figure 1). No significant increase in V β 17-positive cells is observed in the non-RA arthritis or SLE patients when compared with the normal controls. Taken together, these results demonstrate a selective expansion of V β 17-positive T cells in the PB of RA patients.

Table 1
Summary of T Cell Phenotypes of RA and Control Subjects
% of CD3-Positive Cells*

T Cell Antigen: (Monoclonal Antibody)	CD4 (OKT4)	CD8 (Anti-Tac)	IL-2R p55 (C37)	V β 2/5.3 (OT145)	V β 6.7a V β 8 (16G8)	(SS11)	%
Peripheral Blood							
Normal Subjects	71.0	$\pm 8.9(14)$	30.4	$\pm 11.3(14)$	4.5	$\pm 2.9(14)$	2.7
SLE		54.5 $\pm 11.8(13)$		42.1 $\pm 14.1(13)$	6.8	$\pm 8.0(13)$	2.9 $\pm 1.4(11)$
Non-RA Arthritis							
Non-RA Arthritis		54.9 $\pm 14.7(7)$		41.4 $\pm 16.8(8)$	12.6 $\pm 19.2(7)$	3.5 $\pm 1.8(7)$	3.1 $\pm 1.6(7)$
RA	70.1 $\pm 19.3(27)$		37.0 $\pm 18.7(27)$	8.9 $\pm 7.7(27)$	3.4 $\pm 1.8(22)$	3.2* $\pm 2.5(28)$	5.3 ± 5
Synovial Fluid							
Non-RA Arthritis		6.24 $\pm 18.6(15)$		31.3 $\pm 14.1(15)$	9.5 $\pm 4.4(15)$	3.1 $\pm 1.9(17)$	3.6 $\pm 2.1(17)$
RA		53.9 $\pm 16.8(46)$		48.7 $\pm 13.0(45)$	12.3 $\pm 6.6(45)$	3.8 $\pm 2.1(45)$	3.7 $\pm 2.4(48)$
Synovial Tissue							
RA		63.2 $\pm 15.2(19)$		41.6 $\pm 23.1(19)$	9.7 $\pm 7.0(20)$	2.6 $\pm 2.2(17)$	3.8 $\pm 2.7(21)$

*Isolated T cells were analyzed by indirect immunofluorescence on a cytometer. The percentage of CD-3 positive cells expressing each T cell surface antigen was determined. Shown are the means \pm standard deviation and the number of individuals analyzed () for each subject group studied.

** $p = 0.002$

*** $p = 0.001$

Example 3

To characterize the T cell repertoire at the site of pathology in patients with RA, the synovial fluid, SF T cells were isolated from 49 patients with seropositive RA and analyzed for TCR V β gene usage by indirect immunofluorescence staining (Table 1 and Figure 1). The mean percentage of CD3-positive cells reactive with the V β 17-specific mAb C1 is significantly elevated ($p = 0.001$) in the RA patients (8.5% + 4.1) when compared with the percentage V β 17-positive cells in the 19 SF specimens from patients with non-RA inflammatory arthritis (5.3% + 2.0). Strikingly, 31% (15/49) of the RA fluid samples and 0/19 of the control samples contain greater than 10% V β 17-positive T cells (Figure 1). In contrast, no significant differences were noted between RA and control SF in the percentages of V β 5.2/5.3, V β 6.7a, V β 8, or V β 12-positive T cells.

A representative study of SF T cells from an RA patient with an elevated percentage of V β 17-positive T cells is presented in Figure 2. Analysis of the TCR repertoire in this patient shows 17.3% of cells expressing the V β 17 gene product, but only 2.8%, 2.4%, and 1.9% expressing the V β 5.2/5.3, V β 6.7a, and V β 12 products, respectively. Thus, of the five TCR V β gene families studied, only V β 17 is significantly increased in expression at the site of disease in the RA patients. While we do not have HLA typing data on all of our subjects, an increased percentage of V β 17-positive T cells in RA SF does not appear to correlate directly with expression of the DR4 RA susceptibility allele in these patients. To date, 4 of the 15 patients with >10% V β 17-positive SF T cells have been HLA typed, and their DR haplotypes are: DR 4,7; DR2,3; DRw13; and DR5,7.

Example 4

Two color immunofluorescence analysis was performed on 5 RA SF samples and on 3 non-RA inflammatory arthritis SF samples, all of which contained less than 10% V β 17-positive T cells (Table 2). Th SF cells were stained with anti-V β 3 or

anti-V β 17 mAb and FITC-goat anti-mouse IgG, followed by phycoerythrin anti-IL-2 receptor antibody (anti-p55-TAC) and immunofluorescence was assessed on a cytofluorograph. The Tac-positive cells are found almost exclusively among the CD4-positive SF T cells from the RA patients. Moreover, Tac-positive T cells were enriched among the V β 17-positive T cells from the RA SF, but not from the non-RA arthritis SF. Cytofluorograph histograms demonstrating Tac expression on a high proportion of V β 17-positive T cells (approximately 45%), but not V β 3-positive T cells (less than 10%), from an RA SF specimen are shown in Figure 3. Thus, even RA SF that do not contain a markedly expanded V β 17-positive T cell population show evidence for preferential activation of that T cell fraction, when compared with T cells expressing other V β gene products.

15

Example 5

In order to assess the pathogenic potential of V β 17⁺ synovial tissue T cells, an informative RA patient was analyzed. This patient has "classic" rheumatoid factor-positive (RF⁺) 20 polyarticular, symmetrical joint inflammation, expresses the RA associated MHC class II antigen DR4 and exhibits an expanded V β 17⁺T cell population. Over an eighteen month period of study, this patient maintained a skewed peripheral blood T cell repertoire characterized by persistently elevated percentages of 25 V β 17⁺T cells, i.e. 13.2-15.7% as compared to an average normal value of 5.3%.

After the 18 month period, synovial tissue was explanted from the patient by an arthroscopic synovectomy and the synovial T cells were isolated to use in: 1) analysis of cell surface antigen expression; 2) molecular characterization of α /B 30 TCR rearrangements; and 3) in vitro propagation and cloning of V β 17⁺ T cell clones.

In order to analyze the cell surface antigen expression, synovial tissue T cells were washed in phosphate-buffered saline (PBS) and stained with a panel of monoclonal 35

antibodies as described in Example 1. T cells were incubated with buffer alone or a saturating concentration of mAb at 4°C for 30 minutes, washed three times with PBS, and incubated with a saturating concentration of flurescein-labeled F(ab'), fragments 5 of goat anti-mouse IgG (Tago, Inc., Burlingame, CA) at 4°C for 30 minutes. After 3 washes in PBS, the cells were analyzed on a cytofluorograph. Two color immunofluorescence analysis were performed using phycoerythrin-labeled anti-CD4 and anti-CD8 mAb obtained from Coulter Immunology (Hialeah, FL). The above 10 procedure was followed by a blocking step, with cells incubated at 4°C for 30 minutes with an irrelevant murine mAb (anti-trinitrophenol). After three washes, the cells were incubated with a phycoerythrin-labeled murine mAb, washed, and analyzed on an Ortho IIIs cytofluorograph, gating on the small, nongranular 15 lymphocyte population. The percentage of cells fluorescent with buffer or irrelevant control murine mAb and flurescein-labeled goat anti-mouse IgG alone was subtracted. The results are shown in Table 3.

Table 3

	CD4	CD8	v β 3	v β 5.2/3	v β 6.7a	v β 8	v β 12	v β 17
% mAb $^+$ T cells	72.3	29.2	4.8	2.6	1.5	1.6	3.2	7.9
% mAb $^+$ T cells which are CD4 $^+$	100	0	30	31	10	50	50	89

18

19

Table 2
Distribution of Tac-Positive Cells Among Synovial T Cell Subpopulations
& of Total Tac+ In T Cell Population*

T Cell Population	RA Synovial Fluids			Non-RA Arthritis Synovial Fluids		
	CD4	CD8	CD45	CD4	CD8	CD45
CD4	79.3	89.9	81.6	100	90.3	86.2
CD8	3.4	10.9	18.4	0	11.1	50.8
					14.8	27.6
V β 3	0	4.3	N.D.	3.4	N.D.	N.D.
V β 5.2,5.3	3.4	8.7	6.8	4.8	6.6	3.1
V β 6.7 α	6.9	4.3	1.9	10.9	13.1	6.9
=V β 12 _{5.2}	3.4	4.3	3.9	6.8	8.2	4.6
					3.7	3.7
V β 17	48.3	21.7	10.7	18.4	18.0	4.6
						3.4

*Two color immunofluorescence analysis was performed on RA or non-RA SF T cells using phycoerythrin-labeled anti-IL-2 receptor mAb and either anti-CD4, anti-CD8, or anti-TCR V β mAb followed by FITC-labeled goat anti-mouse IgG. The distribution of the total Tac-positive T cells between CD4 and CD8 subsets, and among the 5 TCR V β populations tested, was calculated by determining the % of cells positive with both anti-IL-2 receptor and anti-T cell mAb/the % of IL-2 receptor-positive cells.

As shown in the table, the distribution of V β 17 $^{+}$ T cells in this patient's peripheral blood reflected the overall CD4/CD8 ratio (1/4), however, synovial tissue TCR repertoire analysis with mAbs demonstrated relative abundance of V β 17 $^{+}$ T cells and their selective presentation in the CD4 $^{+}$ subset.

5

Example 6

In order to assess oligoclonality of V β 17 $^{+}$ T cells at the site of pathology of RA, sequences of the highly polymorphic antigen binding CDR3 region in the V β 17 transcripts were examined. The V β 17 transcripts were derived from the synovial tissue and peripheral blood of the RA patient described in Example 5. These transcripts were analyzed using reverse transcriptase-polymerase chain reaction (RT-PCR) with total cellular RNA as a template.

15

Total cellular RNAs were isolated from the peripheral blood or synovial tissue T cells by the guanidinium/cesium chloride centrifugation method or an acidified guanidinium/phenol/chloroform method as described in the manual of (RNazol™, TEL-TEST, INC., Texas. The first-strand cDNAs were reverse transcribed with cDNA synthesis kit (cDNA Cycle Kit, Invitrogen, San Diego, California). TCR V β gene segments were amplified by polymerase chain reaction (PCR) with the 5' sense oligonucleotide primers specific for V β 17 (5'-ACAGCGTCTCTGGGAGA-3') (seq. I.D. No. 15), V β 6.7 (5'-AGGCAACAGTGCACCAGAC-3') (seq. I.D. No. 16), V β 1 (5'-GCACAAACAGTTCCCTGACTT-3') (seq. I.D. No. 17), in connection with a antisense primer complementary to TCR β constant region sequence (5'-GGGTGTGGGAGATCTCTGCT-3') (seq. I.D. No. 18). The PCR products were subcloned into a T/A cloning vector according to the instruction manual provided by Invitrogen, San Diego, CA. The ligation mixture was used to transform competent DH5 α cells. The plasmid DNA samples were prepared and subject to sequencing using a sequencing kit (Sequenase version 2.0, United States Biochemical, OH).

20

25

30

A total of twenty-nine (29) V β 17 cDNA clones from synovial tissue T cells were sequenced. Twelve (12) of the twenty-nine (29) clones contain the identical sequence. Eleven (11) of the twenty-nine (29) clones contain a distinct but 5 structurally-related sequence. The two dominant synovial tissue sequences are designated V β 17seq1 and V β 17seq2, respectively. The nucleotide and deduced amino acid sequences in CDR3 region 10 are shown in Figure 4. Comparison of these sequences reveals identity in length as well as conservation of several amino acids with the CDR3 region, including isoleucine (I) at position #95 15 and asparagine at position #99.

In contrast, V β 17 transcripts from the RA patients peripheral blood were heterogeneous. Twenty-eight cDNA clones were sequenced and twenty-two distinct patterns of CDR3 sequences 15 were present. None of the peripheral blood cDNA clones contained the dominant synovial tissue V β 17 sequences.

Example 7

Rearrangements of V β 6.7a and V β 1 gene subfamilies were 20 also assessed in order to ensure that the clonal dominance of the synovial RNA samples of Example 6 were not an aspect of the PCR amplification.

As shown in Table 3, V β 6.7a $^+$ T cells represent only 1.5% of synovial T-cells, 6 distinct rearrangements were observed 25 in the 8 clones sequenced. Three distinct rearrangements in 9 V β 1 T cell clones sequenced were found. These rearrangements were totally heterogeneous with respect to CDR3 sequences and the JB segment usage.

The results described in this Example, along with the 30 previous examples, demonstrate that V β 17 $^+$ T cells express structurally related CDR3 sequences are selectively expanded in the synovial tissue of RA patients.

Example 8

In order to examine the possible role played by T cells expressing these dominant V β 17 sequences in the rheumatoid process, synovial tissue T cells were isolated and expanded in vitro. Synovial tissue cells were incubated at 1 x 10⁶/ml in 5 RPMI 1640, 10% fetal calf serum, 1% penicillin and streptomycin, 1% glutamine (culture medium) containing V β 17 selective microbial superantigen *Mycoplasma arthritidis* mitogen (MAM, from Dr. B. Cole, University of Utah School of Medicine, Salt Lake City, 10 Utah) at a final concentration of 1/2000, or 10 μ g/ml of anti-V β 17 mAb C1.

As described in Friedman et al., *J. Exp. Med.* 174, 891 (1991), after 4 days of culture at 37°C, purified interleukin 2 (IL-2) (Schiapparelli, Columbia, MD) was added to each culture at 15 a final concentration of 10%. TCL were further expanded by the weekly addition of x-irradiated sodium periodate-treated 20 allogeneic peripheral blood non-T cells and IL-2.

While a large number of distinct V β 17 TCR sequences are represented among the bulk T cell lines (TCLs) generated, two 25 V β 17 transcripts from 1 TCL, designated culture 5, were analyzed using the method of Example 6. As shown in Fig. 4, the first transcript from culture 5, termed V β 17seq3, utilizes V β 17-D β 2-J β 2.1-C β 2. This sequence is highly homologous to the dominant synovial tissue sequences, V β 17seq1 and V β 17seq2.

The second V β 17 transcript from culture 5, V β 17seq4, 30 shares the amino acid residue "I" at position #95 and "N" at position #99 with V β 17seq1, 2, and 3 (Fig.4).

Example 9

α chain usage by the culture 5-derived T cell clones 35 expressing V β 17seq3 and 4 was analyzed. The Culture 5 TCL cells were cloned by limited dilution using 5x10⁴ x-irradiated periodate-treated allogeneic feeder cells and IL-2, then further expanded with epriodate-treated feeder cells and IL-2.

TCR α rearrangements were analyzed using PCR and a panel of V α specific primers from a TCR α constant region primer, (J. R. Oksenberg et al., *Nature* 345: 344 (1990)), except primers for the V α 2 subfamily and for the TCR α chain constant region sequence. The sense oligonucleotide primer for V α 2, 5'AGGTCGACGAATGATGAAATCCTTGAGAG-3' (seq. I.D. No. 19), is located at the 5' leader of V α 2 coding sequence and contains a Sal I site inside for further subcloning. The 3' antisense oligonucleotide complementary to TCR α constant region sequence is 5'-AATAGGTCGACAGACTTGTCACTGG-3' (seq. I.D. No. 20) in which two nucleotides have been changed to create a Sal I site for future subcloning purpose.

This analysis revealed expression of only V α 2.3 by T cell clone expressing V β 17seq3. Formal sequencing was performed and yielded a sequence consisting of V α 2.3-J α (IGRJa09)-C α (Fig. 5). This V α designation is consistent with positive staining of this T cell clone by the V α 2.3 specific mAb F1 (Janson et al., 1989, *Cancer Immunol. Immunother.* 28: 225). A similar analysis of T cells expressing the V β 17seq4 has yield a TCR α rearrangement of V α 3.1-J α -C α (Fig. 5). Thus, both TCR α and β chain of T cell clones expressing receptors homologous to the dominant synovial tissue V β 17 transcripts have been characterized.

25 Example 10

The culture 5 derived T cell clones were assayed for proliferative response against a panel of Epstein-Barr virus (EBV) transformed DR homozygous lymphoblastoid B cell lines (BCL). As a control, an uncloned synovial tissue V β 17+, CD4+ T cell line designated culture 10 was assayed simultaneously (Fig. 6). 2×10^4 T cell line cells were cultured, in triplicate, in 96 well round-bottom tissue cultures plates with medium alone or with 5×10^4 EBV-transformed HLA DR homozygous B cell line cells (from Dr. S. Y. Yang, Sloan Kettering Institute, New York, NY) x-irradiated with 4000 rads from a Cesium source. Cultures were

supplemented with 5% IL-2 and after 96 hours, 2 μ Ci 3 [H]-thymidine added to each culture and 16 hours later, the cultures were transferred to filter paper using an automated cell harvester and counted in a beta counter. Clones expressing 5 $V\alpha 2.3/V\beta 17\text{seq}3$ showed poor growth characteristics and low levels of proliferation in response to all stimuli, including superantigens and anti-TCR mAb. However, as shown in the upper panel of Fig. 6, these cells proliferate selectively to BCL cells expressing RA associated alleles of DR4, Dw4 and Dw14. T cells 10 expressing $V\alpha 3.1/V\beta 17\text{seq}4$ are highly responsive to DR4, Dw10 bearing BCL cells (lower panel of Fig. 6). This preliminary evidence of DR4 recognition by synovial T cells expressing the conserved CDR3 sequences is intriguing. It is not clear, however, if these clones recognize as yet undefined antigenic 15 peptides in association with alleles of this MHC class II antigen or are specific for the DR4 alleles themselves.

25
SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANT: Friedman, Steven M
Crow, Mary K
Yi, Y.
Tumang, Joseph
Sun, Guang-Rong

(ii) TITLE OF INVENTION: Conserved T-Cell Receptor Sequences

(iii) NUMBER OF SEQUENCES: 21

(iv) CORRESPONDENCE ADDRESS:

(A) ADDRESSEE: Darby & Darby PC
(B) STREET: 805 Third Avenue
(C) CITY: New York
(D) STATE: New York
(E) COUNTRY: US
(F) ZIP: 10022

(v) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Floppy disk
(B) COMPUTER: IBM PC compatible
(C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: PatentIn Release #1.0, Version #1.25

(vi) CURRENT APPLICATION DATA:

(A) APPLICATION NUMBER:
(B) FILING DATE:
(C) CLASSIFICATION:

(viii) ATTORNEY/AGENT INFORMATION:

(A) NAME: Ludwig, S. Peter
(B) REGISTRATION NUMBER: 25,351
(C) REFERENCE/DOCKET NUMBER: 5983/09449

(ix) TELECOMMUNICATION INFORMATION:

(A) TELEPHONE: 212-527-7700
(B) TELEFAX: 212-753-6237
(C) TELEX: 236687

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 23 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

- (v) FRAGMENT TYPE: internal
- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Homo sapiens
- (vii) IMMEDIATE SOURCE:
 - (B) CLONE: vb17 seq 1-aa

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

Cys	Ala	Ser	Ser	Ile	Gly	Gln	Glu	Asn	Tyr	Glu	Gln	Tyr	Phe	Gly	Pro
					5					10					15
1															
Gly Thr Arg Leu Thr Val Thr															
20															

(2) INFORMATION FOR SEQ ID NO:2:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 69 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: cDNA to mRNA
- (iv) ANTI-SENSE: NO
- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Homo sapiens
- (vii) IMMEDIATE SOURCE:
 - (B) CLONE: Vb17-seq 1-nt

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

TGTGCCAGTA GTATTGGTCA GGAGAACTAC GAGCAGTACT TCGGGCCGGG CACCAGGCTC	60
ACGGTCACA	69

(2) INFORMATION FOR SEQ ID NO:3:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 22 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:
(A) ORGANISM: *Homo sapiens*

(vii) IMMEDIATE SOURCE:
(B) CLONE: vb17-seq2-aa

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:

Cys Ala Ser Ser Ile Gln Gly Tyr Asn Glu Gln Phe Phe Gly Pro Gly
1 5 10 15

Thr Arg Leu Thr Val Leu
20

(2) INFORMATION FOR SEQ ID NO:4.

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 66 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA to mRNA

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:
(A) ORGANISM: *Homo sapiens*

(vii) IMMEDIATE SOURCE:
(B) CLONE: vb17-seq2-nt

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1

TGTGCCAGTA GTATACAGGG GTACAATGAG CAGTTCTTCG GGCCAGGGAC ACGGCTCACC
CTGCCTA

60

66

(2) INFORMATION FOR SEQ ID NO:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 22 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(v) FRAGMENT TYPE: interv.

(vi) ORIGINAL SOURCE:
(A) ORGANISM: Homo sapiens

(vii) IMMEDIATE SOURCE:
 (B) CLONE: vb17-seq3-aa

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

Cys	Ala	Ser	Ser	Ile	Gly	Gln	Thr	Asn	Glu	Gln	Phe	Phe	Gly	Pro	Gly
1				5					10				15		
Thr	Arg	Leu	Thr	Val	Leu										
			20												

(2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 66 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA to mRNA

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:
 (A) ORGANISM: Homo sapiens

(vii) IMMEDIATE SOURCE:
 (B) CLONE: vb17-seq3-nt

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

TGTGCCAGTA GTATCGGGCA GACGAATGAG CAGTTCTTCG GGCCAGGGAC ACGGCTCAC
 60
 GTGCTA
 66

(2) INFORMATION FOR SEQ ID NO:7:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 22 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:
 (A) ORGANISM: Homo sapiens

(vii) IMMEDIATE SOURCE:
 (B) CLONE: vb17-seq4-aa

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

Cys	Ala	Ser	Ser	Ile	Pro	Arg	Ala	Asn	Glu	Gln	Phe	Phe	Gly	Pro	Gly
1				5					10						15
Thr	Arg	Leu	Thr	Val	Leu										
				20											

(2) INFORMATION FOR SEQ ID NO:8:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 66 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA to mRNA

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo sapiens

(vii) IMMEDIATE SOURCE:

- (B) CLONE: vb17-seq4-nt

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

TGTGCCAGTA GTATAACCCCG GGCCAATGAG CAGTTCTTCG GGCCAGGGAC ACGGCTCACG	60
GTGCTA	66

(2) INFORMATION FOR SEQ ID NO:9:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 66 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA to mRNA

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo sapiens

(vii) IMMEDIATE SOURCE:

- (B) CLONE: vb17-seq4-nt

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

WO 95/28481

30

TGTGCCAGTA GTATAACCCCG GGCCAATGAG CAGTTCTTCG GGCCAGGGAC ACGGCTCACG 60
 66

GTGCTA

(2) INFORMATION FOR SEQ ID NO:10:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 27 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(v) FRAGMENT TYPE: internal

- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Homo sapiens

- (vii) IMMEDIATE SOURCE:
 - (B) CLONE: Va2.3-aa

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

Cys	Val	Val	Lys	Gly	Gly	Gly	Asn	Lys	Leu	Val	Phe	Gly	Ala	Gly	Thr
1				5					10					15	
	Ile	Leu	Arg	Val	Lys	Ser	Tyr	Ile	Gln	Asn	Pro				
				20					25						

(2) INFORMATION FOR SEQ ID NO:11:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 81 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA to mRNA

(iv) ANTI-SENSE: NO

- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Homo sapiens

- (vii) IMMEDIATE SOURCE:
 - (B) CLONE: Va2.3-nt

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

TGTGTGGTGA AGGGAGGGGG AAACAAGCTG GTCTTGGCG CAGGAACCAT TCTGAGAGTC 60

AAGTCCTATA TCCAGAACCC T

(2) INFORMATION FOR SEQ ID NO:12:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 28 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(v) FRAGMENT TYPE: internal

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo sapiens

(vii) IMMEDIATE SOURCE:

- (B) CLONE: Va3.1-aa

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

Cys	Ala	Thr	Leu	Gly	Gly	Ser	Asn	Tyr	Lys	Leu	Thr	Phe	Gly	Lys	Gly
1				5					10					15	

Thr	Leu	Leu	Thr	Val	Asn	Pro	Asn	Ile	Gln	Asn	Pro				
			20					25							

(2) INFORMATION FOR SEQ ID NO:13:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 84 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA to mRNA

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo sapiens

(vii) IMMEDIATE SOURCE:

- (B) CLONE: Va3.1-nt

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

TGTGCTACAC TGGGAGGTAG CAACTATAAA CTGACATTG GAAAAGGAAC TCTCTTAACC
 GTGAATCCAA ATATCCAGAA CCCT

WO 95/28481

32

(2) INFORMATION FOR SEQ ID NO:14:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 5 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (v) FRAGMENT TYPE: internal
- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Homo sapiens
- (vii) IMMEDIATE SOURCE:
 - (B) CLONE: V-D junction

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

Ile Gly Gln Xaa Asn
1 5

(2) INFORMATION FOR SEQ ID NO:15:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 5 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (v) FRAGMENT TYPE: internal
- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Homo sapiens
- (vii) IMMEDIATE SOURCE:
 - (B) CLONE: RA-DR peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

Gln Lys Arg Ala Ala
1 5

(2) INFORMATION FOR SEQ ID NO:16:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 18 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single

- (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: cDNA to mRNA
- (iv) ANTI-SENSE: NO
- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Homo sapiens
- (vii) IMMEDIATE SOURCE:
 - (B) CLONE: VB17-5' PRIMER
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

ACAGCGTCTC TCGGGAGA

18

(2) INFORMATION FOR SEQ ID NO:17:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 19 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: cDNA to mRNA
- (iv) ANTI-SENSE: NO
- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Homo sapiens
- (vii) IMMEDIATE SOURCE:
 - (B) CLONE: VB 6.7- 5' PRIMER
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:

AGGCAACAGT GCACCAGAC

19

(2) INFORMATION FOR SEQ ID NO:18:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 21 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: cDNA to mRNA
- (iv) ANTI-SENSE: NO
- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Homo sapiens

WO 95/28481

34

(vii) IMMEDIATE SOURCE:
 (B) CLONE: Vb1- 5' PRIMER

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:

GCACAAACAGT TTCCCTGACT T

21

(2) INFORMATION FOR SEQ ID NO:19:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 20 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA to mRNA

(iv) ANTI-SENSE: YES

(vi) ORIGINAL SOURCE:
 (A) ORGANISM: Homo sapiens

(vii) IMMEDIATE SOURCE:
 (B) CLONE: TCR B -ANTISENSE

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:

GGGTGTGGGA GATCTCTGCT

20

(2) INFORMATION FOR SEQ ID NO:20:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 29 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA to mRNA

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:
 (A) ORGANISM: Homo sapiens

(vii) IMMEDIATE SOURCE:
 (B) CLONE: Va2 5' PRIMER

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:

AGGTCGACGA ATGATGAAAT CCTTGAGAG

29

(2) INFORMATION FOR SEQ ID NO:21:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 25 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA to mRNA

(iv) ANTI-SENSE: YES

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo sapiens

(vii) IMMEDIATE SOURCE:

- (B) CLONE: TCR_a 3' antisense

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:

AATAGGTCGA CAGACTTGTC ACTGG

WHAT IS CLAIMED:

1 1) A purified and isolated DNA comprising a DNA sequence
2 encoding the CDR3 region of the T cell receptor found in the
3 synovial tissue of RA patients.

1 2) A purified and isolated DNA of claim 1, comprising a
2 DNA sequence encoding the V β region of the CDR3, V β 17seq1, as set
3 forth in Figure 3.

1 3) A purified and isolated DNA of claim 1, comprising a
2 DNA sequence encoding the V β region of the CDR3, V β 17seq2, as set
3 forth in Figure 3.

1 4) A purified and isolated DNA of claim 1, comprising a
2 DNA sequence encoding the V β region of the CDR3, V β 17seq3, as set
3 forth in Figure 3.

1 5) A purified and isolated DNA of claim 1, comprising a
2 DNA sequence encoding the V β region of the CDR3, V β 17seq4, as set
3 forth in Figure 3.

1 6) A purified and isolated DNA of claim 1, comprising a
2 DNA sequence encoding the V α region of the CDR3, V α 2.3-
3 J α (IGRJa09)-C α , as set forth in Figure 4.

1 7) A purified and isolated DNA of claim 1, comprising a
2 DNA sequence encoding the V α region of the CDR3, V α 3.1-Jak-C α , as
3 set forth in Figure 4.

1 8) A polypeptide comprising the CDR3 region of the T cell
2 receptor found in the synovial tissue of RA patients.

1 9) A polypeptide of claim 8, comprising the V β region of
2 the CDR3, V β 17seq1 and having the amino acid sequence set forth
3 in Figure 3.

1 10) A polypeptide of claim 8, comprising the V β region of
2 the CDR3, V β 17seq2 and having the amino acid sequence set forth
3 in Figure 3.

1 11) A polypeptide of claim 8, comprising the V β region of
2 the CDR3, V β 17seq3 and having the amino acid sequence set forth
3 in Figure 3.

1 12) A polypeptide of claim 8, comprising the V β region of
2 the CDR3, V β 17seq4 and having the amino acid sequence set forth
3 in Figure 3.

1 13) A polypeptide of claim 8, comprising the V β region of
2 the CDR3, and having the amino acid sequence IGQ_N.

1 14) A polypeptide of claim 8, comprising the V α region of
2 the CDR3, V α 2.3-J α (IGRJa09)-C α , and having the amino acid
3 sequence set forth in Figure 4.

1 15) A polypeptide of claim 8, comprising the V α region of
2 the CDR3, V α 3.1-J α k-C α , as set forth in Figure 4.






FIGURE 1


FIGURE 2



3/6

FIGURE 3

IL2R-PE



IL2R-PE




FIGURE 4

	---- V β ----	---- N-D-N ----	----- J β -----
β 17seq1 (STTC, J β 2.7)	C A S S TGTGCCAGTAGT	I G Q E N ATTGGTCAGGAGAAC	Y E Q Y F G P G T R L T V T TACGAGCAGTACTCGGGCGGGCACAGGCTCAOGGTACA
β 17seq2 (STTC, J β 2.1)	C A S S TGTGCCAGTAGT	I Q G ATACAGGGG	Y N E Q F F G P G T R L T V L TACAATGAGCAGTTCTCGGGCCAGGGACACGGCTCAOGGTGCTA
β 17seq3 (Cult 5, J β 2.1)	C A S S TGTGCCAGTAGT	I G Q T ATCGGGCAGAOG	N E Q F F G P G T R L T V L AATGAGCAGTTCTCGGGCCAGGGACACGGCTCAOGGTGCTA
β 17seq4 (Cult 5, J β 2.1)	C A S S TGTGCCAGTAGT	I P R A ATACCCCGGGCC	N E Q F F G P G T R L T V L AATGAGCAGTTCTCGGGCCAGGGACACGGCTCAOGGTGCTA

FIGURE 5

(A) V α 2.3-J α (IGRJa09) -C α


-- V α -- -- V-J -- ----- J α ----- C α -----
C V V K G G G N K L V F G A G T I L R V K S Y I Q N P
TGTGTGGTG AAGGGAGGG GGAAACAAAGCTGGCTTTGGCGAGGAACCATTCTGAGAGTCAGTCAAGTCTAT ATCCAGAACCT

(B) V α 3.1-J α k-C α

-- V α -- -V-J- ----- J α ----- C α -----
C A T L G G S N Y K L T F G K G T L L T V N P N I Q N P
TGTGCTACA CTG GGAGGTAGCAACTATAAACTGACATTGGAAAAGGAACTCTCTAACCGTGAATCCAAAT ATCCAGAACCT

FIGURE 6

Stimulator BCL DR allele



INTERNATIONAL SEARCH REPORT

International application No.
PCT/US95/04803

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) :Please See Extra Sheet.

US CL :536/23.1, 23.5, 23.53; 530/300, 324, 325, 326, 330; 435/69.1

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 536/23.1, 23.5, 23.53; 530/300, 324, 325, 326, 330; 435/69.1

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS; STN files Biosis, Medline, EMBASE, CA, WPIDS (search terms include: T cell receptor; V.alpha; V.beta, V.beta.17; rheumatoid arthritis (RA); synovial); Sequence search.

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US, A, 4,886,743 (HOOD ET AL.) 12 December 1989, see entire document.	1-15
Y	Journal of Clinical Investigation, Volume 90, issued August 1992, W. Williams et al., "Restricted Heterogeneity of T Cell Receptor Transcripts in Rheumatoid Synovium", pages 326-333, see entire document.	1-15
Y	US, A, 5,298,396 (KOTZIN ET AL.) 29 March 1994, see entire document.	1-5, 8-13

 Further documents are listed in the continuation of Box C.

See patent family annex.

* Special categories of cited documents:	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be of particular relevance	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"B" earlier document published on or after the international filing date	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&"	document member of the same patent family
"O" document referring to an oral disclosure, use, exhibition or other means		
"P" document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search
06 JULY 1995

Date of mailing of the international search report

18 JUL 1995Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231
Facsimile No. (703) 305-3230Authorized officer *Nehas Feynor*
ARIE M. MICHELSON, PH.D.
Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

International application No. PCT/US95/04803

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	Proceedings of the National Academy of Sciences USA, Volume 88, issued December 1991, M. Howell et al., "Limited T-cell Receptor β -Chain Heterogeneity Among Interleukin 2 Receptor-Positive Synovial T Cells Suggests a Role for Superantigen in Rheumatoid Arthritis", pages 10921-10925, see entire document.	1-5, 8-13
Y	Journal of Experimental Medicine, Volume 177, issued June 1993, H. DerSimonian et al., "Clonal V- α -12.1 $^{+}$ T Cell Expansions in the Peripheral Blood of Rheumatoid Arthritis Patients", pages 1623-1631, see entire document.	6-7, 14-15
Y	WO, A, 93/04695 (WILLIAMS ET AL.) 18 March 1993, see entire document.	1-15
Y,P	Journal of Clinical Investigation, Volume 94, issued November 1994, J. Goronzy et al., "Dominant Clonotypes in the Repertoire of Peripheral CD4 $^{+}$ T Cells in Rheumatoid Arthritis", pages 2068-2076, see entire document.	1-5, 8-13

Form PCT/ISA/210 (continuation of second sheet)(July 1992)*

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US95/04803

A. CLASSIFICATION OF SUBJECT MATTER:
IPC (6):

C12N 15/00, 15/09, 15/11, 15/12, 15/13; C07K 4/00, 14/00, 14/435, 14/47, 14/725; C07H 21/00, 21/04